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1. Demographics for EEG-MRI group 
 
Table S1. Demographic and clinical variables for participants included in the combined 
EEG-MRI analysis, mean (standard deviation). 
 HC (N=40) AD (N=19) LBD (N=36*) Group differences 
Male: female 25:15 13:6 31:5 χ2=5.5, p=0.06a 
Age 73.4 (6.6)  75.4 (7.1) 75.0 (6.3) F(2,92)=0.8, p=0.45b 
AChEI - 19 32 χ2=2.3, p=0.13c 
PD meds - 0 25 χ2=24.2, p<0.001c 
Duration  - 3.7 (1.7)f 3.3 (2.2)g U=246, p=0.18d  
MMSE 28.8 (1.1) 22.0 (3.4) 23.3 (3.9) t53=1.2, p=0.24
e 
UPDRS III 3.9 (4.2) 1.7 (1.4) 20.4 (8.5) t53=9.5, p<0.001
e 
CAF total - 0.3 (0.8)f 5.0 (4.3)h t50=4.6, p<0.001
e 
Mayo total - 9.1 (4.2)f 14.2 (5.7)h t50=3.4, p=0.001
e 
Mayo cogn - 2.0 (2.0)f 2.9 (1.8)h t50=1.7, p=0.10
e 
NPI total - 7.3 (7.3)f 14.8 (11.1)j t52=2.6, p=0.012
e 
NPI hall - 0.06 (0.2)f 2.0 (2.0)j t52=4.1, p<0.001
e 
AChEI, number of patients taking acetylcholinesterase inhibitors; AD, Alzheimer’s disease; CAF total, 
Clinician Assessment of Fluctuation total score; Duration, duration of cognitive symptoms in years; HC, 
healthy controls; LBD, Lewy body dementia; Mayo total, Mayo Fluctuations Scale; Mayo cognitive, Mayo 
Fluctuation cognitive subscale; MMSE, Mini Mental State Examination; PD meds, number of patients taking 
dopaminergic medication for the management of Parkinson’s disease symptoms; UPDRS III, Unified 
Parkinson’s Disease Rating Scale III (motor subsection); NPI, Neuropsychiatric Inventory; NPI hall, NPI 
hallucination subscore 
a Chi-square test HC, AD, LBD; b One-way ANOVA HC, AD, LBD; c Chi-square test AD, LBD; d Mann 
Whitney U test AD, LBD; e Student’s t-test AD, LBD. 
f N=18, g N=35, h N=34, j N=36 
* 20 DLB and 16 PDD 
  
2. Comparison of DLB and PDD subgroups 
 
Table S2. Demographic and clinical variables comparing DLB and PDD subgroups, mean 
(standard deviation). 
 DLB (N=24) PDD (N=17) Group differences 
Male: female 19:5 16:1 χ2=1.8, p=0.18a 
Age 76.2 (6.4)  72.4 (6.1) t39=1.9, p=0.06
b 
AChEI 22 13 χ2=1.8, p=0.18a 
PD meds 11 17 χ2=13.5, p<0.001a 
LEDD 374.7 (205.4) 867.5 (365.5) t26=4.1, p<0.001
b 
Duration  3.5 (2.4) 2.7 (1.5)d U=159, p=0.36c  
MMSE 22.6 (4.4) 23.8 (2.7) t39=1.0, p=0.31
b 
UPDRS III 16.2 (7.7) 25.8 (6.7) t39=4.1, p<0.001
b 
CAF total 4.3 (4.1)e  6.7 (4.3)f t39=1.7, p=0.10
b 
Mayo total 13.4 (6.0)e 15.7 (4.5)f t39=1.3, p=0.21
b 
Mayo cogn 2.7 (1.7)e 3.4 (1.7)f t39=1.3, p=0.20
b 
NPI total 10.2 (6.4)e 20.3 (12.3) t39=3.4, p=0.002
b 
NPI hall 1.8 (1.9)e 2.4 (2.1) t39=0.9, p=0.37
b 
AChEI, number of patients taking acetylcholinesterase inhibitors; CAF total, Clinician 
Assessment of Fluctuation total score; DLB, Dementia with Lewy bodies; Duration, 
duration of cognitive symptoms in years; LEDD, levodopa equivalent daily dose; Mayo 
total, Mayo Fluctuations Scale; Mayo cognitive, Mayo Fluctuation cognitive subscale; 
MMSE, Mini Mental State Examination; PDD, Parkinson’s disease dementia; PD meds, 
number of patients taking dopaminergic medication for the management of Parkinson’s 
disease symptoms; UPDRS III, Unified Parkinson’s Disease Rating Scale III (motor 
subsection); NPI, Neuropsychiatric Inventory; NPI hall, NPI hallucination subscore 
a Chi-square test DLB, PDD; b Student’s t-test DLB, PDD; c Mann Whitney U test DLB, 
PDD. 




Table S3. Mean [95% confidence interval]. Alpha power and alpha reactivity estimated from 
electrodes O1, Oz, and O2 using individual alpha peak frequencies. NBM volume normalized 
to total intracranial volume. Differences between DLB and PDD were assessed by Student’s 
t-tests. 
 DLB PDD Group comparison 
individual  6.6 6.2 t39=1.3, p=0.20 
alpha peak [6.1, 7.0] [5.9, 6.5]  
alpha reactivity 0.10 0.05 t39=1.0, p=0.31 
[0.02,0.19] [-0.02,0.11]  
eyes closed alpha 
power 
40.3 38.7 t39=0.42, p=0.68 
[34.8, 45.9] [33.1, 44.3]  
eyes open alpha 
power 
37.0 36.3 t39=0.15, p=0.88 
[30.1, 43.9] [31.5, 41.1]  
NBM volume 0.16 0.16 t39=0.47, p=0.64 
 [0.15, 0.17] [0.15, 0.18]  
 
  
3. Alpha reactivity analysis using the standard alpha frequency band  
Instead of using alpha power from individual alpha peak frequencies to estimate alpha 
reactivity, we performed the same analysis using the standard alpha frequency band from 8-
12 Hz (Wan et al., 2019).  
Alpha reactivity was reduced in both dementia groups compared to controls with a 
significantly greater reduction in LBD compared to AD (Supplementary Table S3). 
When considering the whole group (across AD, LBD, and controls), there was a significant 
positive correlation between alpha reactivity and total NBM volume (ρ=0.42, p<0.001). 
When considering each group separately, there was a significant positive correlation in the 
PDD group (ρ=0.66, p=0.006), whereas there were no significant correlations in the other 
three groups (all p>0.05). 
 
Table S4. Mean [95% confidence interval]. Alpha power and alpha reactivity estimated from 
electrodes O1, Oz, and O2 using the standard alpha frequency band from 8-12 Hz. Group 
differences assessed by Kruskal-Wallis ANOVA with post-hoc tests corrected for multiple 
comparisons. 
 HC AD LBD Group comparison 
alpha 
reactivity 
0.50 0.25 -0.01 F2=49.3, p<0.001 
[0.42, 0.59] [0.12, 0.38] [-0.09,0.06] p(HC,AD)=0.01 
p(HC,LBD)<0.001 
p(AD,LBD)=0.01 
AD, Alzheimer’s disease; HC, healthy controls; LBD, Lewy body dementia 
 
  
4. Group comparisons including gender as covariate 
Table S5. Group comparison of EEG characteristics and NBM volume, including gender as 
covariate.  
 HC AD LBD Group comparison 
individual  
alpha peak 
8.8  7.4 6.4 F2=25.3, p<0.001 





0.56 0.23 0.09 F2=54.3, p<0.001 





47.8 33.6 41.4 F2=5.1, p=0.008
  





18.5 24.0 37.2 F2=26.7, p<0.001 
(1.81) (2.48) (1.80) p(HC,AD)= 0.23 
p(HC,LBD)<0.001 
p(AD,LBD)<0.001 
NBM volume 0.19 0.17 0.16 F2=10.8, p<0.001 
 (0.004) (0.005) (0.004) p(HC,AD)=0.003 
p(HC,LBD)<0.001 
p(AD,LBD)=1.0 
Mean (standard error), adjusted for gender covariate. Alpha power and alpha reactivity 
estimated from electrodes O1, Oz, and O2 using individual alpha peak frequencies. NBM 
volume normalized to total intracranial volume. Group differences assessed by univariate 
ANCOVA including gender as covariate, with post-hoc tests corrected for multiple 
comparisons. 
AD, Alzheimer’s disease; HC, healthy controls; LBD, Lewy body dementia; NBM, nucleus 
basalis of Meynert 
  
5. Effect of dopaminergic medication in the LBD group 
 
Table S6. Mean (standard deviation). Alpha power and alpha reactivity estimated from 
electrodes O1, Oz, and O2 using individual alpha peak frequencies. NBM volume normalized 
to total intracranial volume. Differences between LBD patients on dopaminergic mediation 
and LBD patients not on dopaminergic medication were assessed by two-sample Student’s t-
tests. 












individual  6.4 6.3 t39=0.3, p=0.80 ρ=-0.02, p=0.93 
alpha peak (0.86) (1.11)   
alpha reactivity 0.09 0.05 t39=0.7, p=0.46 ρ=-0.27, p=0.17 
(0.18) (0.15)   
eyes closed alpha 
power 
39.1 40.9  t39=0.5, p=0.65 ρ=0.15, p=0.45 
(10.9) (14.8)   
eyes open alpha 
power 
35.3 39.8 t39=1.0, p=0.34 ρ=0.27, p=0.16 
(12.2) (16.8)   
LBD, Lewy body dementia; LEDD, levodopa equivalent daily dose 
 
